Videos

Offering reportedly seamless integration into workflows for prenatal evaluations and real-time decision-making, the cloud-based Delivery Date AI software was trained on millions of ultrasound images from diverse pregnancies.

In a recent interview, Ashesh Jani, M.D., discussed pertinent findings in two post-hoc studies from the SPOTLIGHT trial that examined the efficacy of 18F-flotufolastat PET/CT for detecting biochemical recurrence and bone metastases in patients with prostate cancer.

Full approval of PNT2003, a radioequivalent of Lutathera (lutetium Lu 177 dotatate), is subject to a 30-month stay — triggered by a Hatch-Waxman patent litigation — that is reportedly set to expire in June 2026.

Catch up on the top radiology content of the past week.

In a recent interview, Brian Helfand, M.D., Ph.D., discussed key findings from a multicenter prospective trial, presented at the ASCO-GU symposium, that compared the PET radiotracers 18F-flotufolastat and 18F piflufolastat for urinary radioactivity and detection of PCa recurrence.

In a recent interview from the ASCO-GU conference. Daniel George, M.D., discussed new study findings with 177Lu-PSMA-617 for the treatment of older taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) and potential implications for future research.

The FDA clearance for the AI-enabled chest X-ray software qXR-Detect reportedly includes detection of findings in the lung, pleura, hila and heart, bone and mediastinum.

Offering AI-powered automation features and advanced imaging capabilities, the new LOGIQ E10 series, the LOGIC Fortis™ and the LOGIQ Totus™ ultrasound platforms will be introduced at the European Congress of Radiology in March.

In a recent interview, Nina Kottler, M.D., discussed the agility of agentic AI to achieve system-level goals in radiology, the need for transparency and how agentic AI may affect the future of radiology.

The AKY-1189 agent was designed for targeting of positive Nectin-4 expressing tumors that reportedly occur in 80 to 90 percent of patients with urothelial cancer.

In a recent interview, Jeremy Heit, M.D., Ph.D., discussed key neuroimaging takeaways from changes to the updated guideline from the American Heart Association and the American Stroke Association for early evaluation and management of patients with acute ischemic stroke.

Catch up on the top radiology content of the past week.

Previously approved by the FDA in 2022, the macrocyclic gadolinium-based MRI contrast agent gadopiclenol can now be utilized to detect lesions with abnormal vascularity in the central nervous system and other parts of the body for children under the age of two.

The FDA clearances include the 1.5T SIGNA Sprint with Freelium MRI platform, the 3T SIGNA Bolt MRI system and the AI-powered SIGNA One, which reportedly enhances MRI workflow efficiencies.

In a recent interview, Yulin Ge, M.D., discussed emerging research showing correlations between brain MRI findings in patients with Long Covid and established blood biomarkers for Alzheimer’s disease.

The Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System reportedly enables larger tissue samples and facilitates more efficiency in procedure setup and cleanup with 75 percent less tubing in comparison to other systems.

Emphasizing improved quantification, the Kosmos POCUS platform now offers a biometric application for assessing fetal viability, measurements to facilitate evaluation of the uterus and ovaries, and enhanced reporting for vascular exams.

In the debut of his new “Interventional Radiology in Focus” series, Mina Makary, M.D., discusses the continued emergence of genicular artery embolization as a viable treatment alternative for patients with knee osteoarthritis.

Catch up on the top radiology content of the past week.

In the debut of her new “Breast Imaging in Focus” series, Manisha Bahl, M.D., discusses the recently published Lancet study on AI, mammography and interval breast cancer, and shares her perspective on the potential impact of these findings for breast radiologists.

The use of the SPECT/CT agent 99mTc-maraciclatide may enhance detection and differentiation for interstitial lung disease, which is associated with a large variety of disorders.

In a recent interview, Gary Ulaner, M.D., Ph.D., discussed preliminary research with the newly patented 61Cu-NU101 radiodiagnostic agent and the potential with the agent’s half-life in expanding access to molecular imaging for prostate cancer detection.

In a recent interview, Benjamin Kann, M.D., discussed new research highlighting the capability of an AI foundation model to obtain a variety of diagnostic and prognostic data from brain MRI scans.

For the detection of lung cancer on low-dose CT, the eyonis LCS software reportedly offers greater than 90 percent sensitivity, specificity and negative predictive value (NPV).

Catch up on the top radiology content of the past week.

Flagging DBT images that may warrant a more expedited review, the CogNet AI-MT+ platform can reportedly be integrated into existing IT systems to facilitate workflow efficiencies for radiologists.

In a recent interview from the International Stroke Conference, Jeremy Heit, M.D., Ph.D., discussed new research suggesting that AI may offer better assessment than neuroradiologists of aneurysm growth on computed tomography or magnetic resonance angiography scans.

The Ascent3T Neonatal Magnetic Resonance Imaging System is reportedly the first high-field 3T system geared to neonatal applications.

The CT-based RevealAI-Lung software reportedly offers a Malignancy Similarity Index score to facilitate evaluation of incidental lung nodules.

The Brainomix 360 Stroke Next Generation software reportedly includes automated assessment of net water uptake (NWU), a CT-based biomarker that may improve risk stratification for patients with severe strokes.